Latest Breaking News On - Therapy designation - Page 8 : vimarsana.com

Johnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD).

Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications

Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients.

DUPIXENT Drug Insights and Market Forecasts Report, 2019-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

/PRNewswire/ The "DUPIXENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com s offering. DUPIXENT s potential as a.

DUPIXENT Drug Insights and Market Forecasts Report, 2019-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

DUBLIN, Dec. 1, 2023 /PRNewswire/ The "DUPIXENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. DUPIXENT's potential as a game-changer extends

Atai Life Sciences: A Promising Venture In Psychedelic Therapy Trading Below Cash Value

China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application f

Novartis iptacopan meets primary endpoint in new rare kidney disease trial

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LRPhase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demo.

China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation

AstraZeneca increase guidance for Total Revenue ex COVID-19 medicines and Core EPS